Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Closantel sodium dihydrate is a synthetic, halogenated salicylanilide small molecule anthelmintic widely used in veterinary medicine to treat and control parasitic infections in livestock, particularly sheep and cattle. It is highly effective against liver flukes (*Fasciola hepatica* and *Fasciola gigantica*), blood-sucking gastrointestinal nematodes (*Haemonchus contortus*), and certain larval arthropods (such as *Oestrus ovis* and *Hypoderma* species). The drug primarily acts as a proton ionophore, uncoupling mitochondrial oxidative phosphorylation in the parasite, which disrupts ATP synthesis and leads to metabolic depletion and death. It also suppresses the activities of succinate dehydrogenase and fumarate reductase, and has been shown to inhibit chitinase in filarial nematodes. Originally discovered and developed by Janssen Pharmaceutica in the 1970s, closantel sodium dihydrate is administered orally, subcutaneously, or topically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on closantel sodium dihydrate.